



US010933120B2

(12) **United States Patent**
Vilhelmsen et al.

(10) **Patent No.: US 10,933,120 B2**
(45) **Date of Patent: Mar. 2, 2021**

(54) **COMPOSITIONS OF GLP-1 PEPTIDES AND PREPARATION THEREOF**

(71) Applicant: **Novo Nordisk A/S**, Bagsvaerd (DK)

(72) Inventors: **Thomas Vilhelmsen**, Karslunde (DK);
Helle Eliassen, Koege (DK); **Tue Hansen**, Copenhagen S (DK)

(73) Assignee: **Novo Nordisk A/S**, Bagsvaerd (DK)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/386,589**

(22) PCT Filed: **Mar. 15, 2013**

(86) PCT No.: **PCT/EP2013/055362**

§ 371 (c)(1),

(2) Date: **Sep. 19, 2014**

(87) PCT Pub. No.: **WO2013/139694**

PCT Pub. Date: **Sep. 26, 2013**

(65) **Prior Publication Data**

US 2015/0072926 A1 Mar. 12, 2015

Related U.S. Application Data

(60) Provisional application No. 61/748,840, filed on Jan. 4, 2013.

(30) Foreign Application Priority Data

Mar. 22, 2012 (EP) 12160743
Jan. 31, 2013 (EP) 13153459

(51) **Int. Cl.**

A61K 38/26 (2006.01)

A61K 9/20 (2006.01)

A61K 31/20 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 38/26** (2013.01); **A61K 9/2013**
(2013.01); **A61K 9/2077** (2013.01); **A61K**
31/20 (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) References Cited

U.S. PATENT DOCUMENTS

5,545,618 A 8/1996 Buckley et al.
5,773,647 A 6/1998 Leone-Bay et al.
5,866,536 A 2/1999 Leone-Bay et al.
5,968,899 A 10/1999 Sekine et al.
6,268,343 B1 7/2001 Knudsen et al.
6,458,924 B2 10/2002 Knudsen et al.
7,049,283 B2 5/2006 Ault et al.
7,235,627 B2 6/2007 Knudson et al.
7,271,149 B2 9/2007 Glaesner et al.
8,039,018 B2 10/2011 Majuru et al.

8,053,429 B2 11/2011 Cumming et al.
8,097,698 B2 1/2012 Knudsen et al.
8,536,122 B2 9/2013 Lau et al.
8,648,041 B2 2/2014 Garibay et al.
8,895,694 B2 11/2014 Spetzler et al.
9,067,977 B2 6/2015 Spetzler et al.
9,266,940 B2 2/2016 Wieczorek et al.
9,278,123 B2 3/2016 Sauerberg et al.
9,527,900 B2 12/2016 Linderoth et al.
9,993,430 B2 6/2018 Jensen et al.
10,005,827 B2 6/2018 Spetzler et al.
10,086,047 B2 10/2018 Sauerberg et al.
10,278,923 B2 5/2019 Nielsen et al.
2001/0011071 A1 8/2001 Knudsen et al.
2005/0009748 A1 1/2005 Dinh et al.
2005/0148497 A1* 7/2005 Khan A61K 9/0095
514/11.7
2006/0078622 A1 4/2006 Majuru et al.
2006/0286129 A1 12/2006 Sarubbi
2007/0049557 A1 3/2007 Ahmed et al.
2007/0203058 A1 8/2007 Lau et al.
2007/0224262 A1 9/2007 Majuru et al.
2008/0076705 A1 3/2008 Kodra et al.
2008/0153779 A1 6/2008 Liao et al.
2008/0194676 A1 8/2008 Abbas et al.
2008/0207507 A1 8/2008 Lau et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CN 101010339 A 8/2007
CN 101133082 A 2/2008

(Continued)

OTHER PUBLICATIONS

Felix Kratz, A clinical update of using albumin as a drug vehicle—A commentary *Journal of Controlled Release* 190 (2014) 331-336.*
Beglinger C et al., Pharmacokinetics and Pharmacodynamic Effects of Oral GLP-1 and PYY3-36: A Proof-of-concept Study in Healthy Subjects, *Journal: Clinical Pharmacology & Therapeutics*, Nature Publishing Group, Year: 2008. vol. 84, No. 4, pp. 468-474.
Leonard Thomas W et al., Promoting absorption of drugs in humans using medium-chain fatty acid-based solid dosage forms: GIPET™, *Journal: Expert Opinion Drug Delivery*, Year: 2006, vol. 3(5), pp. 685-692.

Maher Sam et al., Overcoming poor permeability: translating permeation enhancers for oral peptide delivery, *Journal: Drug Discovery Today: Technologies*, Year: 2011, vol. 9, No. 2, pp. e113-e119.

(Continued)

Primary Examiner — Thomas S Heard

(74) *Attorney, Agent, or Firm* — Leon Y. Lum

(57) ABSTRACT

The invention relates to pharmaceutical compositions comprising a first type of granules and a second type of granules, wherein said first type of granules comprises a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and no GLP-1 peptide, and wherein said second type of granules comprises a GLP-1 peptide and no salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, as well as the intermediate granules, processes for the preparation of the granules and compositions, and use thereof in medicine.

28 Claims, No Drawings

Specification includes a Sequence Listing.